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SuperantigenMethods: Patients (older than 18 years) with community-acquired invasive bacteremia
caused by SDSE bacteremia who were undergoing treatment at China Medical University
Hospital from June 2007 to December 2010 were included in this study. Multiplex poly-
merase chain reaction was performed to identify virulence genes of the SDSE isolates. De-
mographic data, clinical presentations, and outcome in patients with SDSE infections were
reviewed and analyzed.
Results: Forty patients with 41 episodes of SDSE bacteremiawere reviewed. Themedian age of
the patients with SDSE infection was 69.7 years; 55% were female and 78% had underlying dis-
eases. Malignancy (13, 33%) and diabetes mellitus (13, 33%) were the most common comorbid-
ities. The 30-day mortality rate was 12%. Compared with the survivors, the non-survivors had a
higher rate of diabetes mellitus (80% vs. 26%), liver cirrhosis (60% vs.11%), shock (60% vs.17%),
STSS (60% vs. 8%), and a high Pittsburgh bacteremia score >4 (40% vs. 6%). Most isolates had
scpA, ska, saga, and slo genes, whereas speC, speG, speH, speI, speK, smez, and ssa genes were
not detected. speA gene was identified only in one patient with STSS (1/6, 17%). All isolates
were susceptible to penicillin, cefotaxime, levofloxacin, moxifloxacin, vancomycin, and line-
zolid.
Conclusion: In invasive SDSE infections, most isolates carry putative virulence genes, such as
scpA, ska, saga, and slo. Clinical SDSE isolates in Taiwan remain susceptible to penicillin cefo-
taxime, and levofloxacin.
Copyrightª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Streptococcus dysgalactiae belongs to Lancefield groups C
and G, and can be categorized into at least five subgroups
historically.1,2 In 1998, with the help of multilocus enzyme
electrophoresis typing and genomic DNA, an updated clas-
sification of S. dysgalactiae was proposed by Vieira et al,3
which defined only alpha-hemolytic or nonhemolytic
group C streptococcus as S. dysgalactiae subsp. dysga-
lactiae (SDSD) and all b-hemolytic groups C and L and
human group G streptococci as S. dysgalactiae subsp.
equisimilis (SDSE).
SDSE colonizes the pharynx, skin, gastrointestinal
tract, and vagina in humans and is a part of the normal
human flora,4,5 whereas SDSD was isolated only from an-
imals.6 Invasive infections caused by SDSE have increas-
ingly been recognized as a human pathogen since
2003.2,7,8 Among these severe infections, streptococcal
toxic shock syndrome (STSS) is of grave concern. STSS
is usually caused by Streptococcus pyogenes (GAS),9
and superantigens such as speA are implicated in the
pathogenesis of STSS. Other virulence factors, such as
streptolysin S (saga), streptolysin O (slo), and streptoki-
nase A (ska), have been suggested to have a significant
role in the pathogenesis of invasive GAS infections.10
Similarly, the several virulence factors of SDSE that
resemble those of GAS possibly play an important role in
the pathogenesis of SDSE infections.1
Previous studies have been devoted to investigate the
pathogenesis of infection caused by SDSD and SDSE; how-
ever, few studies have investigated the association be-
tween specific toxic genes, clinical presentations, and
outcome in patients. This study aims to analyze the asso-
ciation between clinical manifestations, specific toxic
genes including superantigens, and outcome in patients
with invasive infection caused by SDSE bacteremia.Materials and methods
Patients, setting, and definitions
This study was conducted retrospectively at China Medical
University Hospital, a 2000-bed tertiary hospital in central
Taiwan, from June 2007 to December 2010. Inclusion criteria
wereas follows: (1) age>18 years; (2) presence of at least one
positive S. dysgalactiae in the blood culture of patients; and
(3) consistent symptoms and signs of infection (such as fever
and chills) in clinical presentations. Exclusive criteria were
the following: (1) positive blood culture without obvious
clinical symptoms and signs of infection and (2) hospital-
acquired infection. Data on all demographic characteristics,
laboratory data, microbiological data, clinical diagnosis,
treatment, and outcome in patients were collected from
medical records. The primary bacteremia was defined as
bacteremia that did not have the obvious infectious sources
and secondary bacteremia was defined as bacteremia
accompanied with localized infections such as skinesoft tis-
sue infections, bone and joint infection, respiratory tract
infection, and genital tract infection.11 Recurrence of
bacteremia was defined as recurrent positive blood culture
after complete treatment of prior bacteremia.5 Fever was
defined as body temperature>37.8C.12 Shockwas defined as
a systolic blood pressure of 90 mmHg or the use of an
inotropic agent to maintain blood pressure.13 Leukocytosis
was defined as a serum white blood cell level of>11,000/mL.
The severity of bacteremia was evaluated by the Pittsburgh
bacteremia score (PBS), and severely ill was defined as a PBS
of over 4.14,15 STSS was diagnosed according to the criteria
proposed by the Working Group on Severe Streptococcal In-
fections in 1993.16 The outcomemeasure in our study was 30-
day mortality after hospitalization due to any causes. This
studywas approved by the Institutional ReviewBoard of China
Medical University Hospital (102-REC3-079).
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During the study period, a total of 41 blood isolates
(involving 40 patients) of S. dysgalactiae were collected
consecutively in our clinical microbiologic laboratory.
These isolates were preserved in commercially available
trypticase soy broth containing 20% glycerol and stored in a
refrigerator at 70C. The initial bacterial identification of
S. dysgalactiae isolates and antimicrobial susceptibility
testing of minimum inhibitory concentration (MIC) were
performed using an Automated Microbiology System BD
Phoenix system (Becton Dickinson, Sparks, MD, USA). The
breakpoint of MIC was based on the definition of the Clinical
and Laboratory Standards Institute.17
DNA was extracted from 41 isolates using the Genomic
DNA minikit (Geneaid,Taipei,Taiwan). The 16S universal 8F
GAGAGTTTGATCCTGGCTCAG and 16S universal 1942R
TACGGCTACCTTGTTAC-GACT were used for DNA
amplification.18e20 The size of the polymerase chain reac-
tion (PCR) product was approximately 1.5 kb. Sequencing of
the product was performed on a DNA analyzer (ABI 3730XL).
Finally, the sequence was compared with the database of
the National Center for Biotechnology Information (tem-
plate source: S. dysgalactiae subsp. dysgalactiae ATCC
27957; S. dysgalactiae subsp. equisimilis ATCC 12394;
http://www.ncbi.nlm.nih.gov/) for the identification of S.
dysgalactiae subspecies.
Detection of specific virulent genes
Superantigenic genes (speA, speC, speG, speH, speI, speJ,
speK, speL, speM, ssa, smez, spea 1e3, 5, and spea 1e4)
and other specific virulence genes (scpA, ska, slo, and saga)
were identified using the method of multiplex PCR
described in previous studies.7,21 The final reaction volume
(50 mL) contained 25 mL of master mix (DNA polymerase,
dNTP mix, and PCR buffer), 100 ng of template DNA,
200 nM of each superantigenic gene primer pair, and 20 nM
of 16S rRNA primers. DNA amplification was performed
using a GeneAmp PCR System 9700 (Applied Biosystems,
Taipei,Taiwan) with an initial denaturation step at 95C for
15 minutes, followed by 35 cycles (30 seconds at 94C, 90
seconds at 57C, and 90 seconds at 72C). PCR methods for
the identification of other virulence genes were followed
by an initial denaturation step at 94C for 10 minutes,
followed by 35 cycles (45 seconds at 94C, 45 seconds at
50C, and 60 seconds at 72C) and the final extension step
(7 minutes at 72C). Samples were analyzed on a 2.0%
agarose.
Statistical analysis
Continuous variables were analyzed by median and cate-
gorical variables by Chi-square test or Fisher exact test. We
use the stepwise logistic regression analysis to assess the
influence of independent variables on crude mortality in
individuals with SDSE bacteremia .Variables significantly
associated with mortality in the univariate analysis were
entered into the model. All statistical analyses were per-
formed using SPSS software version 12.0 (SPSS, Chicago, IL,USA). All tests were two tailed, with p < 0.05 being
considered statistically significant.Results
A total of 41 blood isolates of S. dysgalactiae were identi-
fied in this study. Based on the results of bacterial identi-
fication using a BD Phoenix system, 30 isolates (73%) were
identified as SDSD and the others as SDSE. Finally, all iso-
lates were confirmed as SDSE by means of 16S rRNA
sequencing with GeneBank.
The comparison of clinical characteristics of patients
with SDSE bacteremia between the survivor and non-survi-
vor groups was summarized in Table 1. Most of the patients
(88%) were over 50 years old, and 18 of them (46%) were
males. Diabetes mellitus, malignancy, and heart disease
were the most common comorbidities observed during this
study. Malignancy (11/35, 31%) was the leading underlying
disease in the survival group, whereas diabetes mellitus (4/
5, 80%) was the most common comorbidity in the non-
survival group. The most common clinical diagnoses were
primary bacteremia (22/41, 54%) and cellulitis (14/41,
34%). Twelve patients had skinesoft tissue infections
involving the lower limbs, and two breast cancer patients
had an upper limb infection. All patients were treated with
appropriate antibiotics, such as b-lactam antibiotic alone
or in combination with glycopeptides, within 2 hours of
diagnosis. Patients with septic arthritis or surgical site
infection received surgical management. One cervical
cancer patient had two episodes of cellulitis at the same
site accompanied with bacteremia within a 2-month
period. The patient was treated successfully with b-lactam
antibiotic alone in both the events. Nine patients devel-
oped shock and six patients had STSS. In this study, the
mortality rate within 30 days was 12%, patients with dia-
betes mellitus or liver cirrhosis, presentation of shock,
STSS, or PBS > 4 were significant poor prognostic factors in
the univariate analysis (Table 1). However, a stepwise lo-
gistic regression model identified no variable independently
associated with mortality after adjustment by patients’ age
and sex (Table 2).
Table 3 shows the distribution of the virulence genes in
patients with or without STSS. More than 95% of the isolates
in the study had invasive, spreading, or nonsuperantigenic
toxic genes, including scpA, ska, saga, and slo genes. By
contrast, superantigenic toxic genes (speC, speG, speH,
speI, speK, smez, and ssa genes) were not found in any
strains. speA gene was detected in one patient with STSS
(1/6, 17%). The association between these specific genes
and clinical presentations (fever, shock, and PBS > 4),
clinical diagnosis (cellulitis, bacteremia, and STSS), and 30-
day crude mortality rate were not statistically significant.
Table 4 shows antimicrobial susceptibility patterns of 41
SDSE clinical isolates. All isolates were susceptible to
penicillin (MIC  0.0312 mg/mL), cefotaxime (MIC  0.5 mg/
mL), levofloxacin (MIC  1 mg/mL), moxifloxacin (MIC 
0.25 mg/mL), and linezolid (MIC  1 mg/mL). However, drug
resistance was remarkable for clindamycin (34%, 14; MIC 
1 mg/mL) and erythromycin (49%, 20; MIC  1 mg/mL).
Table 1 Clinical characteristics of 40 patients with Streptococcus dysgalactiae subspecies equisimilis infectiona,b
Characteristics Total no. of patients (%) No. of survivors (%) No. of nonsurvivors (%) p
Age (y)
>50 35/40 (88) 30/35 (86) 5/5 (100) 0.569
Mean (range) 69.7 (32e96)
Sex
Male 18/40 (45) 15/35 (43) 3/5 (60) 0.439
Underlying disease
Diabetes mellitus 13/40 (33) 9/35 (26) 4/5 (80) 0.013c
End-stage renal disease 8/40 (20) 7/35 (20) 1/5 (20) 0.977
Malignancy 13/40 (33) 11/35 (31) 2/5 (40) 0.671
Liver cirrhosis 7/40 (18) 4/35 (11) 3/5 (60) 0.006c
Heart disease 10/40 (25) 8/35 (23) 2/5 (40) 0.386
Hypertension 10/40 (25) 9/35 (26) 1/5 (20) 0.807
Clinical presentationa
Fever 31/41 (76) 29/36 (80) 2/5 (40) 0.048c
Leukocytosis 32/41 (78) 27/36 (75) 5/5 (100) 0.206
Shock 9/41 (22) 6/36 (17) 3/5 (60) 0.028c
PBS > 4 4/41 (10) 2/36 (6) 2/5 (40) 0.015c
Clinical diagnosisa
Primary bacteremia 22/41 (54) 19/36 (53) 3/5 (60) 0.762
Cellulitis 14/41 (34) 13/36 (36) 1/5 (20) 0.762
STSS 6/41 (15) 3/36 (8) 3/5 (60) 0.002c
Septic arthritis 1/41 (2) 1/36 (3) 0/5 (0) 0.589
Pneumonia 3/41 (7) 2/36 (6) 1/5 (20) 0.245
Endometritis 1/41 (2) 1/36 (3) 0/5 (0) 0.706
Surgical site infectiond 1/41 (2) 1/36 (3) 0/5 (0) 0.706
a Forty patients with 41 bacteremia episodes as one patient had two episodes of bacteremia.
b Nonsurvivors were defined as crude mortality within 30 days after hospitalization.
c Univariate statistical analysis was used to compare between survivor and nonsurvivor groups.
d One patient had left distal tibia fracture and received open reduction with internal fixation.
PBS Z Pittsburgh bacteremia score; STSS Z streptococcal toxic shock syndrome.
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In this study, several important findings weremade. First, the
Phoenix Automated Microbiology System appears to have
limited ability in discriminating between the strains of SDSE
and SDSD.Hence,wemay performmolecular diagnostic tests,
such as 16S rRNA sequencing, for the identification of S. dys-
galactiae subspecies. Second, several putative virulence
genes, including scpA, ska, saga, and slo, were commonly
found in invasive SDSE isolates, but speA, a superantigenic
gene, may not play a significant role in the pathogenesis of
STSS caused by SDSE. Third, penicillin, cefotaxime,Table 2 Multivariate risk factors for 30-day crude mor-
tality rate in patients with Streptococcus dysgalactiae
subspecies equisimilis infection
Categories Odds ratio (95% CI) p
STSS 9.306 (0.77e113.28)* 0.08
Liver cirrhosis 6.089 (0.53e70.18)* 0.15
CI Z confidence interval; STSS Z streptococcal toxic shock
syndrome.
*Adjusted for age and sex.levofloxacin, andmoxifloxacin remain in vitro activity against
SDSE in Taiwan.
Infection caused by SDSE accounts for 5e8% of strepto-
coccus diseases in humans22 and usually occurs in aged
patients or in those with underlying diseases.2,8 The pre-
sentation of STSS and mortality rate in invasive SDSE
infection in our study were similar to those reported else-
where.2,8,23 The current findings, which were similar to
previous studies, showed that diabetes mellitus, malig-
nancy, and heart disease were the common identifiable
underlying diseases in patients with SDSE bacteremia;5,23
however, our study reported a higher percentage of diag-
nosis of primary bacteremia.5,8,24 In this study, we also
found that patients with diabetes mellitus, liver cirrhosis,
shock status, PBS > 4, or complications such as STSS had a
higher 30-day mortality rate in the univariate analysis.
However, none of these variables was statistically signifi-
cant in the multivariate analysis. Perhaps the small sample
size led to insignificant statistical difference. Larger sample
size studies may help to clarify the association between
mortality and risk factors in the future.
The Phoenix Automated Microbiology System (Becton
Dickinson) is a common tool used for bacterial identifica-
tion in clinical practice. In our research, a total of 41 S.
dysgalactiae isolates were identified initially, and 30 of
them (73%) were classified as SDSD. However, SDSD is
Table 3 Distribution of the virulence genes in Strepto-
coccus dysgalactiae subspecies equisimilis isolates from the
patients with or without STSSa
Virulence genesb STSS, no. of
isolates (%)
No STSS, no.
of isolates (%)
Evasion of host immune system
scpA 6/6 (100) 35/35 (100)
Spreading
ska 6/6 (100) 33/35 (94)
Toxins (nonsuperantigenic)
slo 6/6 (100) 34/35 (97)
Saga 6/6 (100) 35/35 (100)
Toxins (superantigenic)
speA 1/6 (17) 4/35 (11)
speC 0/6 (0) 0/35 (0)
speG 0/6 (0) 0/35 (0)
speI 0/6 (0) 0/35 (0)
speJ 1/6 (17) 7/35 (20)
speK 0/6 (0) 0/35 (0)
speL 0/6 (0) 2/35 (6)
speH 0/6 (0) 0/35 (0)
speM 2/6 (33) 5/35 (14)
spea 1e3,5 1/6 (17) 7/35 (20)
spea 1e4 1/6 (17) 3/35 (9)
smez 0/6 (0) 0/35 (0)
ssa 0/6 (0) 0/35 (0)
a No significant differences were observed between two
groups.
b The classification of the virulence genes was based on the
method described by Brandt and Spellerberg.1
STSS Z streptococcal toxic shock syndrome.
466 C.-T. Tsai et al.largely regarded as an animal pathogen6 and only two cases
of SDSD infection in humans have been reported so far in
the English literature.25,26 Therefore, we used 16S rRNA
sequencing with GeneBank to differentiate S. dysgalactiae
blood isolates. All the SDSD isolates were confirmed as SDSE
by 16S rRNA sequencing. This finding suggests that for the
accurate identification of S. dysgalactiae subspecies, mo-
lecular diagnostic tests, such as 16S rRNA sequencing,
appear to be the best choice.
Similar to the findings of Ikebe et al,7 almost all SDSE
isolates in the present study carried scpA, ska, saga, and sloTable 4 Antimicrobial susceptibility patterns of 41 Streptococc
Drug MIC50 (mg/mL) MIC90
Penicillin 0.0312 0.031
Cefotaxime 0.5 0.5
Erythromycin 0.25 >4
Levofloxacin 0.5 1
Moxifloxacin 0.25 0.25
Vancomycin/teicoplanin 0.5/1 0.5/
Linezolid 1 1
Clindamycin 0.125 >2
MIC Z minimal inhibitory concentration.genes, and these nonsuperantigenic virulence genes maybe
play a role in invasive SDSE infection. Superantigenic viru-
lence gene such as speA, similar to those of GAS, have also
been found in SDSE, but previous studies showed that the
association between these superantigenic genes and inva-
sive SDSE infection or STSS is uncertain. Our analysis did not
confirm the association between STSS and speA. A compa-
rable observation was also reported by Hashikawa et al,27
who analyzed 12 strains of group C and G streptococci with
STSS and found no speA gene. Ikebe et al also reported that
the speA gene was not detected in 16 patients with STSS due
to SDSE, while 12 patients did have speG.7 Brandt et al
analyzed superantigens in 46 invasive SDSE isolates, and
speA, speB, speC, speF, speH, speI, speJ, speK, speL, speM,
smeZ, or ssa, were not found. Only six isolates in their study
had speG and two isolates were further identified as having
speGdys.28 These findings were consistent with the current
study that the involvement of speA in the pathogenesis of
invasive SDSE infections, including STSS, is uncertain. The
role of superantigens or associated genes in the pathogenesis
of severe SDSE infections remains unclear.
Erythromycin resistance in streptococci, including group
G streptococci, has been a major health problem,29,30 and
certain strains of SDSE have been reported to be resistant to
newer macrolides in Taiwan.5 In this study, only half of the
isolates were susceptible to erythromycin. Both findings may
suggest that erythromycin is no longer considered a suitable
drug for treating SDSE infections in Taiwan. All the isolates
tested were sensitive to cephalosporin and penicillin; the
result was similar to Takahashi et al’s2 report. All the isolates
were sensitive to vancomycin, teicoplanin, and linezolid.
This is compatible with the Clinical and Laboratory Standards
Institute guideline which suggested that nonsusceptible iso-
lates (penicillin MICs > 0.12 and ampicillin MICs > 0.25 mg/
mL) are extremely rare in b-hemolytic streptococcus, and
routine penicillin susceptibility tests may not be required.17
Fluoroquinolone-resistant SDSE was first reported in Europe
and North America31 and was detected in Japan and Portugal
as well.2,32 However, all our SDSE isolates were sensitive to
levofloxacin and moxifloxacin. This was similar to the find-
ings of a previous study conducted in Taiwan.5 This finding
suggests that fluoroquinolone remains a reliable antimicro-
bial agent for SDSE infection in Taiwan.
Several limitations were found in this study. First, the
study population is small, which may underestimate the
association between specific toxic genes and clinicalus dysgalactiae subspecies equisimilis isolates
(mg/mL) Range (mg/mL) No. of susceptible
isolates (%)
2 0.0312 41/41 (100)
0.5 41/41 (100)
0.0625e>4 21/41 (51)
0.5e1 41/41 (100)
0.25 41/41 (100)
1 0.5/1 41/41 (100)
1 41/41 (100)
0.0625e>2 27/41 (66)
S. dysgalactiae subsp. equisimilis bacteremia 467presentations. Studies with a large sample size may help
clarify the relationship between toxic genes and clinical
presentations. Second, this study was conducted at a single
site; it is unclear if the results can be applied to other sites
or populations. Third, no testing of other putative virulence
determinants such as M protein, C5a peptidase, and
streptokinase was performed; this might have influenced
our conclusion. Fourth, we did not use positive and nega-
tive control strains in the bacterial identification or
detection of genes, and this may affect the accuracy of
identification of some virulence genes.
In conclusion, putative virulence genes, such as scpA,
ska, saga, and slo, were often present in invasive SDSE
isolates, but speA may play an insignificant role in the
pathogenesis of STSS due to SDSE. Penicillin, cefotaxime,
and levofloxacin remain to be reliable antimicrobial agents
against SDSE in Taiwan. Further prospective molecular
studies are warranted to clarify the relationship between
toxic genes and clinical manifestations in invasive SDSE
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